IL6 and idiopathic pulmonary fibrosis: IL-6 inhibitors significantly reduced the risk of idiopathic pulmonary fibrosis (OR= 0.278, 95% [CI], 0.138–0.558; P <0.001), Parkinson’s disease (OR = 0.354, 95% CI, 0.215–0.582; P <0.001), and positively influenced the causal relationship with Type 2 diabetes (OR = 0.759, 95% CI, 0.637–0.905; P = 0.002).